Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028.

2.

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

Homsi J, Daud AI.

Cancer Control. 2007 Jul;14(3):285-94. Review.

PMID:
17615535
3.

Pericytes and vessel maturation during tumor angiogenesis and metastasis.

Raza A, Franklin MJ, Dudek AZ.

Am J Hematol. 2010 Aug;85(8):593-8. doi: 10.1002/ajh.21745. Review.

4.

PDGF and vessel maturation.

Hellberg C, Ostman A, Heldin CH.

Recent Results Cancer Res. 2010;180:103-14. doi: 10.1007/978-3-540-78281-0_7. Review.

PMID:
20033380
5.

Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.

Bauman JE, Eaton KD, Martins RG.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4632-6. Review.

6.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
7.

Antiangiogenic drugs in ovarian cancer.

Kumaran GC, Jayson GC, Clamp AR.

Br J Cancer. 2009 Jan 13;100(1):1-7. doi: 10.1038/sj.bjc.6604767. Epub 2008 Nov 11. Review.

8.

VEGF-targeting therapy for breast cancer.

Sledge GW Jr.

J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):319-23. Review.

PMID:
16924373
9.
10.

New ways to successfully target tumor vasculature in ovarian cancer.

Yang X, Shen F, Hu W, Coleman RL, Sood AK.

Curr Opin Obstet Gynecol. 2015 Feb;27(1):58-65. doi: 10.1097/GCO.0000000000000136. Review.

11.

Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis.

Gianni-Barrera R, Bartolomeo M, Vollmar B, Djonov V, Banfi A.

Biochem Soc Trans. 2014 Dec;42(6):1637-42. doi: 10.1042/BST20140234. Review.

PMID:
25399582
12.

Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A.

Int J Mol Sci. 2013 Jul 30;14(8):15885-909. doi: 10.3390/ijms140815885. Review.

13.

Pericyte-targeting drug delivery and tissue engineering.

Kang E, Shin JW.

Int J Nanomedicine. 2016 May 27;11:2397-406. doi: 10.2147/IJN.S105274. eCollection 2016. Review.

14.

Pericytes: gatekeepers in tumour cell metastasis?

Gerhardt H, Semb H.

J Mol Med (Berl). 2008 Feb;86(2):135-44. Epub 2007 Sep 22. Review.

PMID:
17891366
15.

Targeting pericytes for angiogenic therapies.

Kelly-Goss MR, Sweat RS, Stapor PC, Peirce SM, Murfee WL.

Microcirculation. 2014 May;21(4):345-57. doi: 10.1111/micc.12107. Review.

16.

Endothelial/pericyte interactions.

Armulik A, Abramsson A, Betsholtz C.

Circ Res. 2005 Sep 16;97(6):512-23. Review.

Supplemental Content

Support Center